Association of Inhaled Corticosteroids with Incident Pneumonia and Mortality in COPD Patients; Systematic Review and Meta-Analysis

Overview

Journal COPD

Publisher Informa Healthcare

Specialty Pulmonary Medicine

Date 2015 Dec 10

PMID 26645797

Citations 21

Authors

Emir Festic

Vikas Bansal

Ena Gupta

Paul D Scanlon

Affiliations

Soon will be listed here.

Abstract

Background: Inhaled corticosteroids are commonly prescribed for patients with severe COPD. They have been associated with increased risk of pneumonia but not with increased pneumonia-associated or overall mortality.

Methods: To further examine the effects of inhaled corticosteroids on pneumonia incidence, and mortality in COPD patients, we searched for potentially relevant articles in PubMed, Medline, CENTRAL, EMBASE, Scopus, Web of Science and manufacturers' web clinical trial registries from 1994 to February 4, 2014. Additionally, we checked the included and excluded studies' bibliographies. We subsequently performed systematic review and meta-analysis of included randomized controlled trials and observational studies on the topic.

Results: We identified 38 studies: 29 randomized controlled trials and nine observational studies. The estimated unadjusted risk of pneumonia was increased in randomized trials: RR 1.61; 95% CI 1.35-1.93, p < 0.001; as well as in observational studies: OR 1.89; 95% CI 1.39-2.58, p < 0·001. Six randomized trials and seven observational studies were useful in estimating unadjusted risk of pneumonia -case-fatality: RR 0.91; 95% CI 0.52-1.59, p = 0.74; and OR 0.72; 95% CI 0.59-0.88, p = 0.001, respectively. Twenty-nine randomized trials and six observational studies allowed estimation of unadjusted risk of overall mortality: RR 0.95; 95% CI 0.85-1.05, p = 0.31; and OR 0.79; 95% CI 0.65-0.97, p = 0.02, respectively.

Conclusions: Despite a substantial and significant increase in unadjusted risk of pneumonia associated with inhaled corticosteroid use, pneumonia fatality and overall mortality were found not to be increased in randomized controlled trials and were decreased in observational studies.

Citing Articles

Survival benefit of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: a nationwide cohort study.

Shin J, Park S, Lee J, Lee J Sci Rep. 2024; 14(1):14703.

PMID: 38926519 PMC: 11208440. DOI: 10.1038/s41598-024-65763-1.

Inhaled corticosteroid treatment and pneumonia in patients with chronic obstructive pulmonary disease - nationwide development from 1998 to 2018.

Klitgaard A, Ibsen R, Lykkegaard J, Hilberg O, Lokke A Eur Clin Respir J. 2024; 11(1):2359768.

PMID: 38817947 PMC: 11138226. DOI: 10.1080/20018525.2024.2359768.

Risk of Pneumonia in Patients with COPD Initiating Fixed Dose Inhaled Corticosteroid (ICS) / Long-Acting Bronchodilator (LABD) Formulations Containing Extrafine Beclometasone Dipropionate versus Patients Initiating LABD Without ICS.

Price D, Henley W, Cancado J, Fabbri L, Kerstjens H, Papi A Pragmat Obs Res. 2024; 15:1-16.

PMID: 38274639 PMC: 10807314. DOI: 10.2147/POR.S438031.

Inhaled corticosteroids and adverse outcomes among chronic obstructive pulmonary disease patients with community-acquired pneumonia: a population-based cohort study.

Basille D, Wang L, Thomsen R, Menon J, Shetty N, Duhaut P Front Med (Lausanne). 2023; 10:1184888.

PMID: 37554496 PMC: 10405521. DOI: 10.3389/fmed.2023.1184888.

Effects of Inhaled Corticosteroids on the Innate Immunological Response to Infection in Patients with COPD.

Ceron-Pisa N, Shafiek H, Martin-Medina A, Verdu J, Jordana-Lluch E, Escobar-Salom M Int J Mol Sci. 2022; 23(15).

PMID: 35897707 PMC: 9332726. DOI: 10.3390/ijms23158127.

References

Wouters E, Postma D, Fokkens B, Hop W, Prins J, Kuipers A . Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax. 2005; 60(6):480-7. PMC: 1747438. DOI: 10.1136/thx.2004.034280. View

Ko F, Ip M, Chan P, Ng S, Chau S, Hui D . A one-year prospective study of infectious etiology in patients hospitalized with acute exacerbations of COPD and concomitant pneumonia. Respir Med. 2008; 102(8):1109-16. PMC: 7127638. DOI: 10.1016/j.rmed.2008.03.019. View

Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S . Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003; 21(1):74-81. DOI: 10.1183/09031936.03.00031402. View

Anzueto A, Ferguson G, Feldman G, Chinsky K, Seibert A, Emmett A . Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD. 2009; 6(5):320-9. DOI: 10.1080/15412550903140881. View

Tashkin D, Doherty D, Kerwin E, Matiz-Bueno C, Knorr B, Shekar T . Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. Int J Chron Obstruct Pulmon Dis. 2012; 7:73-86. PMC: 3276258. DOI: 10.2147/COPD.S29444. View

Aaron S, Vandemheen K, Fergusson D, Maltais F, Bourbeau J, Goldstein R . Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007; 146(8):545-55. DOI: 10.7326/0003-4819-146-8-200704170-00152. View

Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J . Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015; 313(7):677-86. DOI: 10.1001/jama.2015.88. View

van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C . Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med. 2002; 166(10):1358-63. DOI: 10.1164/rccm.200206-512OC. View

Ferguson G, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C . Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med. 2008; 102(8):1099-108. DOI: 10.1016/j.rmed.2008.04.019. View

10.

Singh S, Amin A, Loke Y . Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009; 169(3):219-29. DOI: 10.1001/archinternmed.2008.550. View

11.

Kerwin E, Scott-Wilson C, Sanford L, Rennard S, Agusti A, Barnes N . A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD. Respir Med. 2013; 107(4):560-9. DOI: 10.1016/j.rmed.2012.12.014. View

12.

Mahler D, Wire P, Horstman D, Chang C, Yates J, Fischer T . Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002; 166(8):1084-91. DOI: 10.1164/rccm.2112055. View

13.

Paggiaro P, Dahle R, BAKRAN I, Frith L, Hollingworth K, Efthimiou J . Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet. 1998; 351(9105):773-80. DOI: 10.1016/s0140-6736(97)03471-5. View

14.

Calverley P, Stockley R, Seemungal T, Hagan G, Willits L, Riley J . Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest. 2010; 139(3):505-512. DOI: 10.1378/chest.09-2992. View

15.

Ernst P, Suissa S . Pneumonia in elderly patients with chronic obstructive pulmonary disease. Curr Infect Dis Rep. 2008; 10(3):223-8. DOI: 10.1007/s11908-008-0037-4. View

16.

Ernst P, Gonzalez A, Brassard P, Suissa S . Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med. 2007; 176(2):162-6. DOI: 10.1164/rccm.200611-1630OC. View

17.

Doherty D, Tashkin D, Kerwin E, Knorr B, Shekar T, Banerjee S . Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD. Int J Chron Obstruct Pulmon Dis. 2012; 7:57-71. PMC: 3276257. DOI: 10.2147/COPD.S27320. View

18.

Gershon A, Campitelli M, Croxford R, Stanbrook M, To T, Upshur R . Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease. JAMA. 2014; 312(11):1114-21. DOI: 10.1001/jama.2014.11432. View

19.

Sellares J, Lopez-Giraldo A, Lucena C, Cilloniz C, Amaro R, Polverino E . Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia. Am J Respir Crit Care Med. 2013; 187(11):1241-8. DOI: 10.1164/rccm.201209-1732OC. View

20.

Kardos P, Wencker M, Glaab T, Vogelmeier C . Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006; 175(2):144-9. DOI: 10.1164/rccm.200602-244OC. View